Le rapport
Analyses approfondies du financement des entreprises, des stratégies de croissance et des insights de marché des entreprises les plus innovantes du monde
6 rapports et plus encore
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Biotech Kinaset Therapeutics secures $103 million Series B for inhalable pan-JAK inhibitor treating severe asthma.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Annexon Biosciences raises $125M Series D at $750M valuation
Annexon Biosciences raises $125M in Series D at $750M valuation. Classical complement pathway inhibitors...
Crystalys Therapeutics Raises $205M Series A to Transform Biotech
Crystalys Therapeutics has secured $205M Series A in funding to accelerate growth and innovation in the biotech sector. Clinical-stage biopharmaceutical company developing next-generation oral URAT1 inhibitor dotinurad for the treatment of ...
Annexon Biosciences Raises $125M in Series D
Annexon Biosciences, a Biotech company based in 180 Kimball Way, South San Francisco, CA 94080, has raised $125M in Series D at a $750M valuation led by GV, Alta Partners, Omega Funds, Cowen Healthcare Investments, Redmile Group.
Braveheart Bio Raises $185 million in Series A
Braveheart Bio, a Biotechnology company based in San Francisco CA, has raised $185 million in Series A at a Undisclosed led by Andreessen Horowitz.
Affichage de 6 rapports • Page 1 • Catégorie : all
Restez en avance sur le marché
Recevez des insights hebdomadaires dans votre boîte de réception. Pas de spam, juste de l'intelligence.